Impact of niraparib on reducing the platelet count in patients with ovarian cancer

Our real-world data reaffirmed that thrombocytopenia is a significant adverse event that affects the continuation of NIRA and requires careful monitoring. Adjusting the start time to ensure an adequate baseline PLT may help mitigate this risk, but larger-scale studies are needed to validate these findings.